Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. - Wikidata - wikimedia - TriplyDB

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

http://www.wikidata.org/entity/Q43584208

about

The glycaemic outcomes of Cinnamon, a review of the experimental evidence and clinical trials Treatment of prediabetes Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention Pioglitazone increases whole body insulin sensitivity in obese, insulin-resistant rhesus monkeys Practical combination therapy based on pathophysiology of type 2 diabetes The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?Phytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterations Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studies Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome.Actos Now for the prevention of diabetes (ACT NOW) study.Activation of PPAR gamma induces profound multilocularization of adipocytes in adult mouse white adipose tissues.Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.Effect of 8 weeks of overfeeding on ectopic fat deposition and insulin sensitivity: testing the "adipose tissue expandability" hypothesis.PPAR gamma and human metabolic disease Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes Thiazolidinediones in the treatment of type 2 diabetes.Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study.Pioglitazone and sulfonylureas: effectively treating type 2 diabetes PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism Peroxisome proliferator-activated receptor-γ activation enhances insulin-stimulated glucose disposal by reducing ped/pea-15 gene expression in skeletal muscle cells: evidence for involvement of activator protein-1 Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes Nonischemic heart failure in diabetes mellitus.Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.Peroxisome proliferator-activated receptors: new players in the field of reproduction.The importance of free fatty acids in the development of Type 2 diabetes.Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors.Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetes PPARs and the kidney in metabolic syndrome.

P2860

Q26782181-32E4027D-1412-4883-AB2D-28FF87F562E3 Q26783350-E64BF90D-5A22-4BB9-A9AD-425093E5E820 Q26851905-B8C4CA9D-5082-41FB-8D18-CAE786638803 Q27307174-946170FD-A8CB-4E1D-B7DF-E9EFF327D496 Q28076530-6FC02A65-0934-4E62-9B5E-D2EF3105656E Q28222372-C67BC6FA-8B5A-427B-A29A-1C82A26B2C6D Q28484781-74040BB0-90BB-465B-A99A-8A752F2FC4E1 Q28575457-94964E6D-D124-4BFC-A8F0-0851E1C6F63D Q33344514-5ECE8C2F-27CC-4E32-B5F7-200FA8798A86 Q33488336-8A26B6D7-C0E0-4568-8713-6E4EDF552B41 Q33575775-E2AD324E-4B5A-4F38-AB44-4BB86B8B7E88 Q33590082-5BBF6BAD-B0C5-4D75-B616-3522877BACA0 Q33797616-20339636-B974-4160-803F-A6D3D9A63F63 Q33880303-9F5C7CC9-62C3-44ED-8BB4-25F4AF9E2D05 Q34139048-6E718070-A293-4144-86CD-C51F4A2626F6 Q34219418-EF22FD96-C279-40E4-BB82-B2DB5114401D Q34416432-DFED0CA0-DE37-4039-A129-C79F916B3610 Q34502676-738E78C5-E9AF-444D-A6B9-C49C3915AC7F Q34509903-FE93090D-3A73-4025-883D-447478A700A4 Q34628604-9A80F1FE-AFB6-4503-967E-CC935A958C24 Q34781949-E04D7CE6-32A0-4A37-B41C-1D12139555CD Q35691510-3EF47D0F-8E7D-4F9B-B7E0-052D087478AB Q35987456-EC62B136-1FBE-41CC-98F3-3C9D33C14F32 Q36002095-84C3F8FC-3DE2-4313-83A9-728CD8D00E26 Q36192546-7B78A1F4-E16C-4DD4-8CD8-61DDD70935BC Q36203979-3ADE3698-6CCB-4975-9EBF-FF86C007BA25 Q36374482-0E58FC33-738E-466E-8A0D-C55E8C320853 Q36466778-E94A6569-8FC1-4CC7-9199-08E4C6E3C71C Q36474275-0DB3DFAF-BB9C-4808-8F9B-E7889425C4D5 Q36536205-D14FAFAA-F7EF-49F9-839F-3B4767AB6D96 Q36762969-224F7C49-9B19-4E72-8807-6BE4909C976C Q36812788-62D5D94D-7250-4B0D-A666-212654E8E884 Q36820604-8B0FB665-3074-4835-8EC9-043F179276D5 Q36842541-CA68227E-19E6-470D-B494-AE8F8FEDDA35 Q36903108-CFBC0511-290C-438C-BCF4-996F9DE725BF Q36921672-E01C51F9-4430-469C-9DFE-A0656CB123A2 Q36972810-88DB4EB7-E4C1-486F-9685-7712F15BA767 Q37014815-6517830D-0783-4A11-A879-4AB52A13802A Q37065234-91043B48-9DE0-4250-847B-1C0449C87F63 Q37072216-BD5936F8-0E8F-42A1-8B9B-63C6325B7E09

P2860

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

http://www.wikidata.org/entity/Q43584208

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Improved glycemic control and ...... cts treated with pioglitazone.

@en

Improved glycemic control and ...... cts treated with pioglitazone.

@nl

type

label

Improved glycemic control and ...... cts treated with pioglitazone.

@en

Improved glycemic control and ...... cts treated with pioglitazone.

@nl

prefLabel

Improved glycemic control and ...... cts treated with pioglitazone.

@en

Improved glycemic control and ...... cts treated with pioglitazone.

@nl

P1433

Q43584208-854DB7EB-288D-4F67-9D0A-6704549147F9

P1476

Q43584208-D77A6A83-8437-42AD-B01F-33A3CBFE4302

P2093

Q43584208-1B50900E-3593-43EE-8563-65441E492DA8

Q43584208-1B77FFB4-C59C-4189-9ED3-D4CB556259B1

Q43584208-22CC3348-918A-48B7-ACE3-F1E86D60C319

Q43584208-402ACA7C-CA9C-4BEA-914B-5237599182B3

Q43584208-5F9E3CC9-6C70-433A-A068-9EB04F0F9F31

Q43584208-9D3E5950-603B-42A8-A4CE-19E58DA65169

Q43584208-DDCBFCF5-8342-40E5-A988-CE08D5DC4A6E

Q43584208-EC44EA8B-B13D-4CC1-963A-64E9479970A3

Q43584208-F3AEE3A6-8670-466F-B11C-3A6420132D59

P304

Q43584208-7ADD7B75-0E0C-4EB2-8B5E-9A4766F400C9

P31

Q43584208-456C7BBF-BD22-4446-BD25-54AAE8CB9BF3

P356

Q43584208-1E39C9CA-029A-4137-880F-0A3A85502F29

P407

Q43584208-E17740A1-E978-4378-84B0-3391DA303796

P433

Q43584208-1C00EACC-E16B-4B1C-9509-B3F50756A8DB

P478

Q43584208-DF0B88BB-82FF-461F-9E27-0D043F316449

P577

Q43584208-C685C4A3-6197-48FE-B991-338FF3263F53

P5875

Q43584208-C9E754C5-C7C3-44B7-BFAA-A13DB9D3F5B2

P698

Q43584208-4F0D20CA-91F9-4F6D-AD9B-76694008F319

P921

Q43584208-624ADC2A-49FD-49E8-8A9F-B1717A98A5BB

P356

DIACARE.24.4.710

P1433

P1476

Improved glycemic control and ...... cts treated with pioglitazone.

@en

P2093

Cusi K

http://www.w3.org/2001/XMLSchema#string

DeFronzo RA

http://www.w3.org/2001/XMLSchema#string

Ferrannini E

http://www.w3.org/2001/XMLSchema#string

Glass L

http://www.w3.org/2001/XMLSchema#string

Mahankali A

http://www.w3.org/2001/XMLSchema#string

Mahankali S

http://www.w3.org/2001/XMLSchema#string

Mandarino LJ

http://www.w3.org/2001/XMLSchema#string

Matsuda M

http://www.w3.org/2001/XMLSchema#string

Miyazaki Y

http://www.w3.org/2001/XMLSchema#string

P304

710-719

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DIACARE.24.4.710

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2001-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230896456

http://www.w3.org/2001/XMLSchema#string

P698

11315836

http://www.w3.org/2001/XMLSchema#string

P921